瑞舒伐他汀联合替罗非班对急性冠状动脉综合征并发糖尿病患者PCI术后血清炎症因子水平和肾功能的影响(4)
[ 3 ] TURNER RM，YIN P，HANSON A，et al. Investigating the prevalence，predictors，and prognosis of suboptimal statin use early after a non-ST elevation acute coronary syndrome[J]. J Clin Lipidol，2017，11(1)：204-214.
[ 4 ] TSUJIMOTO T，SUGIYAMA T，SHAPIRO MF，et al. Risk of cardiovascular events in patients with diabetes mellitus on beta-blockers[J]. Hypertension，2017，70(1)：103-110.
[ 5 ] YANG YJ，LEE SH，KIM BS，et al. Combination therapy of rosuvastatin and ezetimibe in patients with high cardiovascular risk[J]. Clin Ther，2017，39(1)：107-117.
, http://www.100md.com
[ 6 ] LAGO IM，NOVAES GC，BADRAN AV，et al. In-lab upfront use of tirofiban may reduce the occurrence of no-reflow during primary percutaneous coronary intervention. a pilot randomized study[J]. Arq Bras Cardiol，2016，107(5)：403-410.
[ 7 ] WU RC，CHOU PT，CHEN LK. Aspirin plus tirofiban inhibit the thrombosis induced by Russell’s viper venom[J]. Thromb J，2016，14(Suppl 1)：38.
[ 8 ] DINGLAS VD，COLANTUONI E，ELY EW，et al. Authors’ response to commentaries on rosuvastatin for delirium and cognitive impairment in sepsis-associated acute respiratory distress syndrome[J]. J Thorac Dis，2016，8(11)：E1534-E1536.
, 百拇医药
[ 9 ] GOH DH，JIN SC，JEONG HW，et al. Mechanical solitaire thrombectomy with low-dose booster tirofiban injection[J]. Neurointervention，2016，11(2)：114-119.
[10] LI W，LIN L，ZHANG M，et al. Safety and preliminary efficacy of early tirofiban treatment after alteplase in acute ischemic stroke patients[J]. Stroke，2016，47(10)：2649- 2651.
[11] IBRAHIM T，EL KARAK F，ARAJI A，et al. Tirofiban-induced thrombocytopenia occurring with crohn’s disease[J]. Case Reports in Cardiology，2016.DOI：0.1155/2016/4605139.
, http://www.100md.com
[12] CHAWLA R，TURLINGTON J，ARORA P，et al. Race and contrast-induced nephropathy in patients undergoing coronary angiography and cardiac catheterization[J]. Int J Cardiol，2017.DOI：10.1016/j.ijcard.2016.12.046.
[13] SATO A，AONUMA K，WATANABE M，et al. Association of contrast-induced nephropathy with risk of adverse clinical outcomes in patients with cardiac catheterization：from the CINC-J study[J]. Int J Cardiol，2017.DOI：10. 1016/j.ijcard.2016.11.019.
[14] YOKOHAMA K，FUKUNISHI S，LI M，et al. Rosuvastatin as a potential preventive drug for the development of hepatocellular carcinoma associated with non-alcoholic fatty liver disease in mice[J]. Int J Mol Med，2016，38(5)：1499-1506.
(收稿日期：2017-08-18 修回日期：2017-12-21)
(編辑：邹丽娟), 百拇医药(杨建军 庞小华 张建明 米庆 牟华明)
[ 4 ] TSUJIMOTO T，SUGIYAMA T，SHAPIRO MF，et al. Risk of cardiovascular events in patients with diabetes mellitus on beta-blockers[J]. Hypertension，2017，70(1)：103-110.
[ 5 ] YANG YJ，LEE SH，KIM BS，et al. Combination therapy of rosuvastatin and ezetimibe in patients with high cardiovascular risk[J]. Clin Ther，2017，39(1)：107-117.
, http://www.100md.com
[ 6 ] LAGO IM，NOVAES GC，BADRAN AV，et al. In-lab upfront use of tirofiban may reduce the occurrence of no-reflow during primary percutaneous coronary intervention. a pilot randomized study[J]. Arq Bras Cardiol，2016，107(5)：403-410.
[ 7 ] WU RC，CHOU PT，CHEN LK. Aspirin plus tirofiban inhibit the thrombosis induced by Russell’s viper venom[J]. Thromb J，2016，14(Suppl 1)：38.
[ 8 ] DINGLAS VD，COLANTUONI E，ELY EW，et al. Authors’ response to commentaries on rosuvastatin for delirium and cognitive impairment in sepsis-associated acute respiratory distress syndrome[J]. J Thorac Dis，2016，8(11)：E1534-E1536.
, 百拇医药
[ 9 ] GOH DH，JIN SC，JEONG HW，et al. Mechanical solitaire thrombectomy with low-dose booster tirofiban injection[J]. Neurointervention，2016，11(2)：114-119.
[10] LI W，LIN L，ZHANG M，et al. Safety and preliminary efficacy of early tirofiban treatment after alteplase in acute ischemic stroke patients[J]. Stroke，2016，47(10)：2649- 2651.
[11] IBRAHIM T，EL KARAK F，ARAJI A，et al. Tirofiban-induced thrombocytopenia occurring with crohn’s disease[J]. Case Reports in Cardiology，2016.DOI：0.1155/2016/4605139.
, http://www.100md.com
[12] CHAWLA R，TURLINGTON J，ARORA P，et al. Race and contrast-induced nephropathy in patients undergoing coronary angiography and cardiac catheterization[J]. Int J Cardiol，2017.DOI：10.1016/j.ijcard.2016.12.046.
[13] SATO A，AONUMA K，WATANABE M，et al. Association of contrast-induced nephropathy with risk of adverse clinical outcomes in patients with cardiac catheterization：from the CINC-J study[J]. Int J Cardiol，2017.DOI：10. 1016/j.ijcard.2016.11.019.
[14] YOKOHAMA K，FUKUNISHI S，LI M，et al. Rosuvastatin as a potential preventive drug for the development of hepatocellular carcinoma associated with non-alcoholic fatty liver disease in mice[J]. Int J Mol Med，2016，38(5)：1499-1506.
(收稿日期：2017-08-18 修回日期：2017-12-21)
(編辑：邹丽娟), 百拇医药(杨建军 庞小华 张建明 米庆 牟华明)